Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | Chief Medical Officer | March 21, 2025 | March 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date March 21, 2025 · Filed March 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2035-03-20 | Direct | 250,000 |
Reported balance
After 2025-03-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-21 · Grant · Acquired 250,000 · Balance 250,000 F1: This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 21, 2025 Filed Mar 25, 2025 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0000950170-25-044343 · ownership.xml · derivative · entry 1 Levisetti Matteo · CIK 0001962444 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2035-03-20 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0000950170-24-070565 · ownership.xml · derivative · entry 1 Levisetti Matteo · CIK 0001962444 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on December 5, 2024. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 260,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0000950170-24-028608 · ownership.xml · derivative · entry 1 Levisetti Matteo · CIK 0001962444 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2034-03-05 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on September 6, 2024. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0000950170-24-018724 · ownership.xml · derivative · entry 1 Levisetti Matteo · CIK 0001962444 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-01-16 F1 · derivative.exercise_date: On January 17, 2023 the Reporting Person was granted an option with vesting subject to the satisfaction of performance-based vesting criteria. The performance-based vesting criteria was deemed satisfied or waived on February 20, 2024 and these shares underlying the option vested in full. Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 16:33 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 82,500 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-23-043278 · doc4.xml · derivative · entry 1 Levisetti Matteo · CIK 0001962444 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2033-07-20 F1 · derivative.exercise_date: This stock option grant becomes exercisable in twenty four equal monthly installments beginning on August 21, 2023. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:02 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0001209191-23-003988 · doc4.xml · derivative · entry 1 Levisetti Matteo · CIK 0001962444 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2033-01-16 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning on 7/17/2023 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.